Identification of CfiA coding genes in Bacteroides fragilis isolates recovered in Argentina. Inconsistencies in CfiA organization and nomenclature

Litterio, Mirta; Cejas, Daniela; Gutkind, Gabriel; Radice, Marcela

doi:10.1016/j.anaerobe.2017.10.003

Cited by 9 publications

(3 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The cfiA-ccrA gene is usually silent and is expressed only if an insertion sequence has inserted upstream of this structural gene, and it has been reported to occur only in B. fragilis (265)(266)(267). Although the cfiA-ccrA gene occurs in Ͻ10% of B. fragilis isolates, it has been reported worldwide, including in Japan, Argentina, China, Slovenia, and the United States, where the incidence of carbapenem-resistant B. fragilis remained Յ2.5% during 2008 through 2012 (266)(267)(268)(269).…”

Section: Carbapenemase-producing Bacteriamentioning

confidence: 99%

Epidemiology of β-Lactamase-Producing Pathogens

Bush

Bradford²

2020

Clin Microbiol Rev

527

440

View full text Add to dashboard Cite

SUMMARY β-Lactam antibiotics have been widely used as therapeutic agents for the past 70 years, resulting in emergence of an abundance of β-lactam-inactivating β-lactamases. Although penicillinases in Staphylococcus aureus challenged the initial uses of penicillin, β-lactamases are most important in Gram-negative bacteria, particularly in enteric and nonfermentative pathogens, where collectively they confer resistance to all β-lactam-containing antibiotics. Critical β-lactamases are those enzymes whose genes are encoded on mobile elements that are transferable among species. Major β-lactamase families include plasmid-mediated extended-spectrum β-lactamases (ESBLs), AmpC cephalosporinases, and carbapenemases now appearing globally, with geographic preferences for specific variants. CTX-M enzymes include the most common ESBLs that are prevalent in all areas of the world. In contrast, KPC serine carbapenemases are present more frequently in the Americas, the Mediterranean countries, and China, whereas NDM metallo-β-lactamases are more prevalent in the Indian subcontinent and Eastern Europe. As selective pressure from β-lactam use continues, multiple β-lactamases per organism are increasingly common, including pathogens carrying three different carbapenemase genes. These organisms may be spread throughout health care facilities as well as in the community, warranting close attention to increased infection control measures and stewardship of the β-lactam-containing drugs in an effort to control selection of even more deleterious pathogens.

show abstract

Section: Carbapenemase-producing Bacteriamentioning

confidence: 99%

Epidemiology of β-Lactamase-Producing Pathogens

Bush

Bradford²

2020

Clin Microbiol Rev

527

440

View full text Add to dashboard Cite

show abstract

“…The cfi A gene may be expressed at diverse levels, depending on the presence of IS upstream cfi A. In B. fragilis , IS 942, IS 1186 , IS 1187 , IS 1188, IS 612 , IS 613 , IS 614, IS 615, IS 616 , IS 4351, have been related to cfiA, with varying promotion efficiency [ 48 , 49 ]. In our study, IS 1186 was detected in only one strain.…”

Section: Discussionmentioning

confidence: 99%

Phenotypic and genotypic identification of carbapenem resistance in Bacteroides fragilis clinical strains

Kierzkowska

Majewska

Karlowicz

et al. 2023

Med Microbiol Immunol

View full text Add to dashboard Cite

Bacteroides fragilis is an important etiological agent of serious infections in humans. Rapid methods, readily adaptable to use in medical laboratories, are needed to detect antibiotic resistance and decrease the likelihood of therapy failure. The aim of this study was to determine the prevalence of B. fragilis cfiA-positive isolates. The second purpose was to investigate the carbapenemase activity in B. fragilis strains by Carba NP test. In the study, 5.2% of B. fragilis isolates are phenotypically resistant to meropenem. The cfiA gene was identified in 6.1% of B. fragilis isolates. The MICs of meropenem were significantly higher in cfiA-positive strains. The presence of the cfiA gene along with the IS1186 was detected in one B. fragilis strain which was resistant to meropenem (MIC 1.5 mg/L). The Carba NP test results were positive for all the cfiA-positive strains, including those susceptible to carbapenems based on their MIC values. A review of the literature revealed that the rate of B. fragilis with the cfiA gene varies from 7.6 to 38.9% worldwide. Presented results are in line with the other European studies. Phenotypic testing with the Carba NP test, it seems to be a viable alternative for the cfiA gene detection in B. fragilis isolates. The positive result obtained is of greater clinical importance than the detection of the gene cfiA.

show abstract

“…For Bacteroides fragilis the WCMS approach was successful in differentiating carbapenem-resistant from susceptible isolates (Nagy et al, 2011; Wybo et al, 2011). The resistance to carbapenems (and other β-lactams) in B. fragilis is conferred to a gene – cfiA – the distribution of which among B. fragilis isolates is largely consistent with phylotypes with isolates belonging to Division II generally harboring the (silent) cfiA gene (Litterio et al, 2017). The corresponding protein, CfiA, has a mass of some 25,200 Da which is generally beyond the spectrum acquisition mass range in WCMS.…”

Section: Identification Of Resistant Phylogroups By Wcmsmentioning

confidence: 99%

One System for All: Is Mass Spectrometry a Future Alternative for Conventional Antibiotic Susceptibility Testing?

Welker

Belkum

2019

Front. Microbiol.

View full text Add to dashboard Cite

The two main pillars of clinical microbiological diagnostics are the identification of potentially pathogenic microorganisms from patient samples and the testing for antibiotic susceptibility (AST) to allow efficient treatment with active antimicrobial agents. While routine microbial species identification is increasingly performed with matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS), routine AST still largely relies on conventional and molecular techniques such as broth microdilution or disk and gradient diffusion tests, PCR and automated variants thereof. However, shortly after the introduction of MALDI-TOF MS based routine identification, first attempts to perform AST on the same instruments were reported. Today, a number of different approaches to perform AST with MALDI-TOF MS and other MS techniques have been proposed, some restricted to particular microbial taxa and resistance mechanisms while others being more generic. Further, while some of the methods are in a stage of proof of principles, others are already commercialized. In this review we discuss the different principal approaches of mass spectrometry based AST and evaluate the advantages and disadvantages compared to conventional and molecular techniques. At present, the possibility that MS will soon become a routine tool for AST seems unlikely – still, the same was true for routine microbial identification a mere 15 years ago.

show abstract

Identification of CfiA coding genes in Bacteroides fragilis isolates recovered in Argentina. Inconsistencies in CfiA organization and nomenclature

Cited by 9 publications

References 35 publications

Epidemiology of β-Lactamase-Producing Pathogens

Epidemiology of β-Lactamase-Producing Pathogens

Phenotypic and genotypic identification of carbapenem resistance in Bacteroides fragilis clinical strains

One System for All: Is Mass Spectrometry a Future Alternative for Conventional Antibiotic Susceptibility Testing?

Contact Info

Product

Resources

About